RA Capital Discloses $200M Pre-Funded Warrant Purchase in Tyra's $400M Offering
TYRA has more than doubled off its 52-week low of $12.115.
Summary
RA Capital Management disclosed a $200M purchase of pre-funded warrants in Tyra Biosciences' recent $400M offering, bringing its beneficial ownership to 19.99% of the company.
Key Events · Ownership and Investor Activity · TYRA
-
RA Capital Purchases $200M in Pre-Funded Warrants
RA Capital Healthcare Fund acquired 9,078,529 pre-funded warrants at $22.029 per warrant for an aggregate purchase price of $199,990,915.34 in the September 2026 Offering.
-
Beneficial Ownership Reaches 19.99% Cap
RA Capital's beneficial ownership is 19.99% of Tyra's common stock, the maximum allowed under the Pre-Funded Warrants' Beneficial Ownership Blocker, which currently limits exercise to 14,130,492 shares.
-
Warrant Terms: $0.001 Exercise Price, No Expiration
The pre-funded warrants have an exercise price of $0.001 per share, are immediately exercisable, and do not expire, with standard anti-dilution adjustments for stock splits and dividends.
-
Follows $400M Underwritten Offering
This purchase is part of Tyra's $400M underwritten offering of 9.08M common shares and 9.08M pre-funded warrants priced at $22.03 per share, announced September 14, 2026.
Analysis · TYRA · Life Sciences
RA Capital Management, a major healthcare investor, purchased $199,990,915.34 of pre-funded warrants in Tyra Biosciences' September 2026 offering, acquiring warrants exercisable for 9,078,529 shares at $22.029 per warrant. This brings RA Capital's beneficial ownership to 19.99% of Tyra's common stock, the maximum allowed under the warrant's Beneficial Ownership Blocker. The purchase represents a significant vote of confidence from a sophisticated life sciences investor, but also creates a substantial overhang of potentially exercisable shares. The 19.99% cap means RA Capital cannot exercise additional warrants without triggering the blocker, limiting immediate dilution but signaling strong institutional demand for Tyra's equity.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TYRA was trading at $24.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $12.12 to $40.65. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.